DEGRO statement on the KEYNOTE-689 trial: Perioperative immunotherapy in combination with adjuvant (chemo-)radiotherapy for resectable locally advanced head and neck cancers

Schnellhardt S, Böke S, Tribius S, Krause M, Haderlein M, Rühle A, Süß C, Linge A, Hecht M, Balermpas P (2026)

Publication Type: Journal article

Publication year: 2026

Journal

Strahlentherapie und Onkologie Urban & Vogel

DOI: 10.1007/s00066-026-02511-6

Authors with CRIS profile

Marlen Haderlein Department of Radiation Oncology

Involved external institutions

Universitätsklinikum des Saarlandes (UKS) DE Germany (DE) Universitätsklinikum Tübingen DE Germany (DE) Asklepios Kliniken DE Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden DE Germany (DE) Universitätsklinikum Leipzig DE Germany (DE) Universitätsklinikum Regensburg DE Germany (DE) Universitätsspital Zürich (USZ) CH Switzerland (CH)

How to cite

APA:

Schnellhardt, S., Böke, S., Tribius, S., Krause, M., Haderlein, M., Rühle, A.,... Balermpas, P. (2026). DEGRO statement on the KEYNOTE-689 trial: Perioperative immunotherapy in combination with adjuvant (chemo-)radiotherapy for resectable locally advanced head and neck cancers. Strahlentherapie und Onkologie. https://doi.org/10.1007/s00066-026-02511-6

MLA:

Schnellhardt, Sören, et al. "DEGRO statement on the KEYNOTE-689 trial: Perioperative immunotherapy in combination with adjuvant (chemo-)radiotherapy for resectable locally advanced head and neck cancers." Strahlentherapie und Onkologie (2026).

BibTeX: Download